Otsuka Pharmaceutical Co., Ltd. has formed Otsuka Europe Development and Commercialization Ltd. (OEDC) to support its European pharmaceutical business. OEDC will be Otsuka’s European R&D headquarters, working with Otsuka Pharmaceutical Europe Ltd. (OPEL) for the development and commercialization of its products. OEDC and OPEL are separate operations based just outside London. This business model aims to increase collaboration of the company’s global business.
 
“We are delighted to establish this new company in the UK,” said Dean Haubrich, president and chief executive officer of OEDC. “We believe that Otsuka has a great deal to contribute to the health and well-being of people in Europe and we look forward to reinforcing our strong, positive presence.”
 
“The opening of OEDC is a very important milestone for Otsuka in Europe,” said Ole Vahlgren, president and chief executive officer of OPEL “This significant long-term investment will strengthen Otsuka Europe’s continued efforts to bring Otsuka’s innovative medicines to patients across Europe.”